Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias

Journal of Medicinal Chemistry
2018.0

Abstract

While mu opioid receptor (MOR) agonists are especially effective as broad-spectrum pain relievers, it has been exceptionally difficult to achieve a clear separation of analgesia from many problematic side effects. Recently, many groups have sought MOR agonists that induce minimal βarrestin-mediated signaling because MOR agonist-treated βarrestin2 knockout mice were found to display enhanced antinociceptive effects with significantly less respiratory depression and tachyphylaxis. Substantial data now exists to support the premise that G protein signaling biased MOR agonists can be effective analgesic agents. We recently showed that, within a chemical series, the degree of bias correlates linearly with the magnitude of the respiratory safety index. Herein we describe the synthesis and optimization of piperidine benzimidazolone MOR agonists that together display a wide range of bias (G/βarr2). We identify structural features affecting potency and maximizing bias and show that many compounds have desirable properties, such as long half-lives and high brain penetration.

Knowledge Graph

Similar Paper

Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias
Journal of Medicinal Chemistry 2018.0
Synthesis, biological, and structural explorations of a series of μ-opioid receptor (MOR) agonists with high G protein signaling bias
European Journal of Medicinal Chemistry 2022.0
Structure–Activity Relationships and Discovery of a G Protein Biased μ Opioid Receptor Ligand, [(3-Methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the Treatment of Acute Severe Pain
Journal of Medicinal Chemistry 2013.0
Progress in the development of more effective and safer analgesics for pain management
European Journal of Medicinal Chemistry 2019.0
G-Protein biased opioid agonists: 3-hydroxy-N-phenethyl-5-phenylmorphans with three-carbon chain substituents at C9
RSC Medicinal Chemistry 2020.0
Synthetic Studies of Neoclerodane Diterpenes from Salvia divinorum: Identification of a Potent and Centrally Acting μ Opioid Analgesic with Reduced Abuse Liability
Journal of Medicinal Chemistry 2016.0
(2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist
European Journal of Medicinal Chemistry 2019.0
A tetrapeptide class of biased analgesics from an Australian fungus targets the µ-opioid receptor
Proceedings of the National Academy of Sciences 2019.0
Synthesis and Structure–Activity Relationships of 5′-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects
Journal of Medicinal Chemistry 2020.0
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists
ACS Medicinal Chemistry Letters 2020.0